Illumina vs Roche – it’s like a thriller

In January the drug company Roche announced its intention to buy Illumina for $5.7 billion. Roche’s CEO Severin Schwan pointed out that he thinks that a fusion of Illumina and Roche would help both companies to move forward in the area of diagnostics with Next Generation Sequencing technology.

However, Illumina insisted that the bid of $5.7 billion is far too low and offered a “poison pill” to its shareholders.

Now Illumina is sued by the shareholders. They accuse Illumina for having a conflicting financial interest since Goldman Sachs could lose hundreds of millions if the Roche offer was accepted (reuters.com)

I am really curious what will happen next in the fight about Illumina. And it certainly strengthens the feeling that the MiSeq could outbeat Roche’s GS Junior.